Sight Sciences (SGHT)
NASDAQ:SGHT
Want to see SGHT full AI Analyst Report?
SGHT Stock Chart & Stats
$4.09
-$0.06(-1.81%)
At close: 4:00 PM EST
$4.09
-$0.06(-1.81%)
Day’s Range― - ―
52-Week Range$3.11 - $9.24
Previous CloseN/A
Volume59.09K
Average Volume (3M)150.61K
Market Cap
$273.68M
Enterprise Value$229.61M
Total Cash (Recent Filing)$84.96M
Total Debt (Recent Filing)$40.89M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding54,409,943
10 Day Avg. Volume244,568
30 Day Avg. Volume150,613
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)6.47
Price to Sales (P/S)5.35
P/FCF Ratio-13.82
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda-7.07
Forecast
1Y Price Target
$8.73Price Target Upside113.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$84.48M
Bulls Say, Bears Say
Bulls Say
Margin Improvement And Path To ProfitabilityImproving margin profile and disciplined expense control create a clearer path to profitability, which can strengthen valuation support and investor confidence.
Standalone MIGS Market DevelopmentA dedicated program to grow the standalone microinvasive glaucoma surgery market and the rebranding to Interventional Glaucoma could drive adoption of OMNI as a differentiated standalone option for surgeons.
TearCare Reimbursement WinsMedicare administrative contractor coverage for TearCare enables targeted commercial efforts and expands the addressable patient population, supporting procedure volume upside.
Bears Say
Competitive Intensity And Pricing RiskIntense competition from larger medtech and pharmaceutical firms, together with possible surgeon fee cuts, could constrain pricing power and procedure volumes.
Conservative Guidance And External DisruptionsManagement's conservative guidance combined with vulnerability to weather‑related disruptions may limit near‑term upside and increase forecast uncertainty.
Surgical Customer Declines And Share RiskDeclines in surgical glaucoma customers signal potential market share erosion in a one‑MIGS environment, which could pressure revenue growth.
Sight Sciences News
SGHT FAQ
What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $3.11 and its highest was $9.24 in the past 12 months.
What is Sight Sciences’s market cap?
Sight Sciences’s market cap is $273.68M.
When is Sight Sciences’s upcoming earnings report date?
Sight Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 72 days.
How were Sight Sciences’s earnings last quarter?
Sight Sciences released its earnings results on May 06, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.066.
Is Sight Sciences overvalued?
According to Wall Street analysts Sight Sciences’s price is currently Undervalued.
Does Sight Sciences pay dividends?
Sight Sciences does not currently pay dividends.
What is Sight Sciences’s EPS estimate?
Sight Sciences’s EPS estimate is -0.15.
How many shares outstanding does Sight Sciences have?
Sight Sciences has 54,409,943 shares outstanding.
What happened to Sight Sciences’s price movement after its last earnings report?
Sight Sciences reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went up 23.023%.
Which hedge fund is a major shareholder of Sight Sciences?
Currently, no hedge funds are holding shares in SGHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sight Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.73 (113.33% Upside)
$8.73 (113.33% Upside)
Hedge Fund Trend
Increased
By 29.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $377.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.17%
12-Months-Change
Fundamentals
Return on Equity
-59.10%
Trailing 12-Months
Asset Growth
-15.41%
Trailing 12-Months
Company Description
Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
SGHT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: the company returned to double‑digit revenue growth, raised 2026 revenue guidance, showed meaningful early traction in the newly reimbursed Interventional Dry Eye market, sustained very strong gross margins, and demonstrated improved cash usage and lower adjusted operating expenses. Challenges remain—most notably continued net losses, concentrated payer coverage for TearCare, early penetration of the dry eye opportunity, and uncertainty around timing of cash from the legal judgment—but these risks were framed as manageable and addressable with targeted commercial investment. On balance the positive progress, guidance raise, margin strength, and improving cash dynamics outweigh the outstanding risks.View all SGHT earnings summariesSGHT Stock 12 Month Forecast
Average Price Target
$8.73
▲(113.33% Upside)
Technical Analysis
Ownership Overview
33.73% Insiders
5.79% Mutual Funds
13.91% Other Institutional Investors
39.62% Public Companies and
Individual Investors